Immune checkpoint inhibitors in cancer therapy
The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …
Top 10 challenges in cancer immunotherapy
Cancer immunotherapy is a validated and critically important approach for treating patients
with cancer. Given the vast research and clinical investigation efforts dedicated to advancing …
with cancer. Given the vast research and clinical investigation efforts dedicated to advancing …
Treatment of muscle‐invasive and advanced bladder cancer in 2020
VG Patel, WK Oh, MD Galsky - CA: a cancer journal for …, 2020 - Wiley Online Library
Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …
Pembrolizumab as second-line therapy for advanced urothelial carcinoma
Background Patients with advanced urothelial carcinoma that progresses after platinum-
based chemotherapy have a poor prognosis and limited treatment options. Methods In this …
based chemotherapy have a poor prognosis and limited treatment options. Methods In this …
Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence
Cancer is associated with higher morbidity and mortality and is the second leading cause of
death in the US. Further, in some nations, cancer has overtaken heart disease as the …
death in the US. Further, in some nations, cancer has overtaken heart disease as the …
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
T Powles, J Bellmunt, E Comperat… - Annals of …, 2022 - annalsofoncology.org
Urothelial carcinoma (UC), also described as bladder cancer, is the 10th most common
cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 …
cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 …
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
P Sharma, M Retz, A Siefker-Radtke, A Baron… - The lancet …, 2017 - thelancet.com
Background Patients with metastatic urothelial carcinoma have a dismal prognosis and few
treatment options after first-line chemotherapy. Responses to second-line treatment are …
treatment options after first-line chemotherapy. Responses to second-line treatment are …
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Background Atezolizumab can induce sustained responses in metastatic urothelial
carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab …
carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab …
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
J Gong, A Chehrazi-Raffle, S Reddi… - Journal for immunotherapy …, 2018 - Springer
Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and
programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy …
programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy …
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single …
AV Balar, D Castellano, PH O'Donnell, P Grivas… - The Lancet …, 2017 - thelancet.com
Background More than half of all patients with advanced urothelial cancer cannot receive
standard, first-line cisplatin-based chemotherapy because of renal dysfunction, poor …
standard, first-line cisplatin-based chemotherapy because of renal dysfunction, poor …